6 курс / Кардиология / Клинические_рекомендации_по_кардиологии_и_коморбидным_болезням

В.А. СНЕЖИЦКИЙ, Н.В. ШПАК

______________________________________________________________________

58.Prognostic value of plasma von Willebrand factor and soluble P- selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation / Conway DS [et al.] // Circulation. – 2003. – Vol. 107. – P. 3133–3140.

59.Prophylaxis of embolic events in patients with atrial fibrillation using low molecular weight heparin / J. Harenberg [et al.] // Semin Thromb Hemost. – 1993. – Vol. 19, №1. – P. 116–121. 21a.

60.Prothrombotic Activity Is Increased in Patients With Nonvalvular Atrial Fibrillation and Risk Factors for Embolism / Hiroshi Inoue [et al.]

//Chest. – 2004. – Vol. 126. – P. 687–692.

61.Relation of C-Reactive Protein Correlates With Risk of Thromboembolism in Patients With Atrial Fibrillation / Senthil K. Thambidorai [et al.] // Am J Cardiol. – 2004. – Vol. 94. – P. 805–807.

62.Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation / Conway DS [et al.] // Am J Cardiol. – 2004. – Vol. 93. – P. 1368–1373.

63.Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation / Conway DS [et al.] // J Am Coll Cardiol. – 2004. – Vol. 43. – P. 2075–2082.

64.RoTEG Coagulation Analyzer – Ein neues System zur intraoperativen Bedside-Gerinnungs diagnostik / A. Calatzis [et al.] // Der Anaesthesist. – 1995. – Vol. 44, № 2. – P. 491–497.

65.Scardi, S. New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins / S. Scardi, C. Giansante // Ital Heart J Suppl. – 2004. – Vol. 5, № 9. – P. 705–711.

66.Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke / Valérie Wolff [et al.] // Stroke. – 2005. – Vol. 36. – P. 17–21.

67.Thrombelastographic coagulation monitoring during cardiovascular surgery with the ROTEG coagulation analyzer / A. Calatzis [et al.]

//J. Hanley & Belfus. – 2000. – P. 215–226.

68.Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer / M.L. Papa1 [et al.] // Exp. Oncology. – 2007. – Vol. 29, № 2. – P. 111–115.

69.Underutilization of antithrombotic therapy in atrial fibrillation

/V. Adhiyaman [et al.] // J R Soc Med. – 2000. – Vol. 93. – P. 138–140.

70.Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans / A.O. Spiel [et al.] // J Thromb Haemost. – 2006. – Vol.4. – P. 411–416.

151